Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

Mayzent ‘Will Change Lives’ of MS Patients Transitioning to SPMS, Novartis Says

Novartis executive Dan Bar-Zohar, MD, discusses Mayzent's recent FDA approval, which is specifically for relapsing forms of MS, including active SPMS.